Scherpereel, Arnaud <br/><br/>
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.  [electronic resource] 

 -  The Lancet. Oncology  02 2019 
 - 239-253 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(18)30765-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Immunological--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Female<br/>Humans<br/>Ipilimumab--administration & dosage<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Mesothelioma--drug therapy<br/>Mesothelioma, Malignant<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Nivolumab--administration & dosage<br/>Pleural Neoplasms--drug therapy<br/>Prospective Studies